Use of bortezomib for prevention and treatment of rejection in sensitized patients

Choli Hartono; Michelle Lubetzky; Meredith J Aull; Stuart Saal; Jose Figueiro; Sandip Kapur; Darshana Dadhania

Use of bortezomib for prevention and treatment of rejection in sensitized patients

Clin Transpl. 2009:499-503.

Authors

Choli Hartono¹, Michelle Lubetzky, Meredith J Aull, Stuart Saal, Jose Figueiro, Sandip Kapur, Darshana Dadhania

Affiliation

¹ Department of Transplantation Medicine, Weill Cornell Medical College/New York-Presbyterian Hospital, New York, New York, USA.

PMID: 20524323

Abstract

We report 2 cases of sensitized patients who were successfully treated with bortezomib therapy resulting in reduction of donor-specific antibodies (DSA). Our cases illustrate the synergistic effects of combination therapy that includes bortezomib on prevention and treatment of AMR in highly sensitized patients. Moving forward, long-term data on sensitized patients treated with bortezomib are needed to fully evaluate the impact of this therapy.

Publication types

Case Reports

MeSH terms

Adult
Boronic Acids / therapeutic use*
Bortezomib
Graft Rejection / prevention & control*
Humans
Immunoglobulins, Intravenous / therapeutic use
Immunosuppressive Agents / therapeutic use
Isoantibodies / blood*
Isoantibodies / drug effects
Kidney Transplantation / immunology*
Male
Plasmapheresis
Protease Inhibitors / therapeutic use*
Pyrazines / therapeutic use*
Young Adult

Substances

Boronic Acids
Immunoglobulins, Intravenous
Immunosuppressive Agents
Isoantibodies
Protease Inhibitors
Pyrazines
Bortezomib